10:39 AM EDT, 03/16/2026 (MT Newswires) -- Spyre Therapeutics ( SYRE ) said Monday that the recruitment for rheumatoid arthritis sub-study under the Skyway phase 2 trial has been completed and week 12 topline data is now expected in Q3.

Additionally, recruitment for the psoriatic arthritis and axial spondyloarthritis sub-studies of Skyway trial remains on track, with week 16 topline readouts slated for Q4, the biotechnology company said.

Spyre Therapeutics ( SYRE ) said that the Skyline platform trial in ulcerative colitis continues to enroll ahead of schedule and that part A readouts will begin in Q2.

Shares of the company were up over 5% in Monday trading.

Price: 42.36, Change: +2.47, Percent Change: +6.18